<DOC>
	<DOCNO>NCT02547922</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety intravenous treatment regimen two dos anifrolumab versus placebo adult subject active proliferative lupus nephritis ( LN ) .</brief_summary>
	<brief_title>Safety Efficacy Two Doses Anifrolumab Compared Placebo Adult Subjects With Active Proliferative Lupus Nephritis</brief_title>
	<detailed_description>This Phase 2 , multicentre , multinational , randomised , double-blind , placebo-controlled study evaluate efficacy safety two intravenous ( IV ) treatment regimens anifrolumab versus placebo take standard care ( SOC ) treatment mycophenolate mofetil ( MMF ) corticosteroid adult subject active proliferative lupus nephritis ( LN ) .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Main 1 . Age 18 70 year time screen 2 . Fulfils least 4 11 criterion revise 1982 ACR classification criterion SLE , least one must : 1 . Positive antinuclear antibody ( ANA ) test ( 1:40 high ) 2 . Elevated antidsDNA antibody screen ( report equivocal positive result ) , per centrallaboratory ; 3 . AntiSmith antibody screen elevate normal ( ie , positive equivocal result ) per central laboratory 3 . Class III ( ±Class V ) Class IV ( ±Class V ) LN accord World Health Organisation ( WHO ) 2003 ISN/RPS classification base renal biopsy obtain within 12 week prior sign ICF screen period : 4 . Urine protein creatinine ratio &gt; 1 gm/gm ( 113.17 mg/mmol ) , obtain 24hour urine collection screen 5 . Estimated glomerular filtration rate ≥35 mL/min/1.73 m2 6 . Must active latent TB either chest radiograph Quantiferon gold test 7 . Women childbearing potential must negative serum betahCG test screen negative urine pregnancy test prior first dose sponsorprovided MMF . Main 1 . Receipt investigational product ( small molecule biologic ) commercially available biologic agent within four week 5 half life prior sign ICF , whichever great 2 . Pure Class V membranous LN renal biopsy obtain within 12 week prior sign ICF screen period 3 . Known intolerance ≤1.0 gm/day MMF 4 . History dialysis within 12 month prior sign ICF expect need renal replacement therapy ( dialysis renal transplant ) within 6 month period enrolment 5 . Subjects , time sign ICF , receive follow immunosuppressive therapy qualify biopsy ( b ) Oral corticosteroid &gt; 0.5 mg/kg/day 8 week ( c ) Oral IV pulse methylprednisolone &gt; 3.0 gm ( cumulative dose ) ( ) IV cyclophosphamide &gt; 2 pulse highdose ( ≥0.5 gm/m2 ) &gt; 4 dos low dose ( 500 mg every 2 week ) ( e ) Average MMF &gt; 2.5 gm/day ( &gt; 1800 mg/day entericcoated mycophenolate sodium ) 8 week ( f ) Tacrolimus &gt; 4 mg/day 8 week 6 . Major surgery within 8 week sign ICF major surgery plan study period 7 . History nonSLE disease require treatment oral parenteral corticosteroid total 2 week within last 24 week prior sign ICF 8 . Confirmed positive test hepatitis B hepatitis C 9 . Any severe herpes infection time prior randomization 10 . Opportunistic infection require hospitalisation parenteral antimicrobial treatment within 3 year prior randomization ( vaginal , oral skin candidiasis exclusionreason ) . 11 . History cancer , apart : 1 . Squamous basal cell carcinoma skin successfully treat 2 . Cervical cancer situ successfully treat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>lupus , nephritis , randomize , placebo , anifrolumab , safety , efficacy , adult</keyword>
</DOC>